I-PFizer ifaka amabhiliyoni amadola ngohlobo olusha lomdlavuza, ukuvuma ngoMsombuluko kwilayisense Uhlobo lwe-Dual - Ukuqondisa umuthi ovezwa njengomuntu kumele - abangela izidakamizwa e-Oncology.
Isiqhwaga sezemithi izokhokha inkampani ye-biotechnology 3sbio $ 1.25 billion ngaphambiliNgamalungelo angaphandle kweChina eya ekwelashweni kwe-SSGJ - 707. I-3SBIO, esekelwe eShenyang, eChina, ingathola imali efinyelela ku- $ 4,8 billion ngokukhokha okwengeziwe uma umuthi ushaya izinjongo ezithile kanye nokuthengisa amakhosi kufanele ekugcineni afike emakethe. I-PFizer izokwenza ukutshalwa kwezimali okungu- $ 100 kwezigidi eziyizigidi eziyizigidi eziyizinkulu e-3SBIO ekuvaleni kwe-Deal's.
Isivumelwano senza i-PFIZERS i-Drugmaker enkulu yakamuva ukubheja ezidakamizweni ezivimba ngasikhathi sinye amaprotheni pd - 1 ne-vegf, ukusayina okusiza ama-tumors avele adlule amasosha omzimba futhi akhule. Igagasi lokutshalwa kwezimali liza ngemuva komuthi owodwa onjalo, u-Ivonescimab, I-KeyTruda ephakeme ye-Merck & CO's immunotherapy Esigabeni esingu-3 esisesikhundleni somdlavuza wamaphaphu eChina ngonyaka owedlule. Izinkampani ezingaphezu kweshumi manje sezibakhulisa. Abaningi basuselwa eChina noma wathola amathemba abo kusuka kubathengisi bezidakamizwa baseChina, ekhombisa Ukukhula komkhakha we-Biotech lapho.
"Kusobala ukuthi zonke [Corporation Ezihlangene] zifuna i-PD - 1 / Vegf ezandleni," kubhala i-jefferies umhlaziyi, "kubhala i-jefferies umhlaziyi,"
Lezi PD - I-1 / Vegf inhibitors zidonsela inzalo ngoba zingakha phezu kwe-Keystruda nezinye izidakamizwa ezinjengayo, ezingaphatha amakhansela bese uthola izigidigidi zamaRandi ekuthengisweni konyaka.
IMIBUZO KONKE, Kodwa-ke. Imiphumela yokutadisha evela eqinisweni le-Ivonescimab eChina yaphakamisa a Inzuzo yesizotha yokusinda ngokuqhathaniswa ne-keyruda, kepha umehluko wawungewonakalise ngokwanele ukufakazela ukuthi i-Ivonescimab ingcono. Akukacaci ukuthi ngabe i-PD - I-1 / Vegf inhibitors izothuthuka kwezindlela ezijwayelekile kwezinye izinhlobo zama-tumor, noma ezivivinyweni zamazwe aphesheya ezinamachibi ahlukahlukene ahlukahlukene.
I-PFizer ngifuna i-oncology Ukusiza ekujikeni isilayidi esidlule sesitoko kanye nemali engenayo yokugoma i-Covid, ne-PD - Izidakamizwa ze-1 / Vegf ziye zaba yingxenye yalowo mzamo. NgoFebhuwari, it Ibambisene ne-Ivonescimab Developers Akeso kanye neNgqungquthela Therapeutics ukutadisha izidakamizwa zabo eceleni kwemithi yomdlavuza epayipini kaPfizer. Manje amalungelo okubamba ama-PFizer ku-Ivonescimab Competitor abhekene namanje abhekene nezilingo ze-China eChina emdlavuza wamaphaphu, umdlavuza we-metastatic imibalabala kanye nama-tumor athile anemibala.
Qaphela:Baphinde babuyiselwe e-biopharmadive. Uma kukhona noma yikuphi ukukhathazeka kwe-copyright, sicela uxhumane neqembu lewebhusayithi ukuze lisuswe.
Isikhathi Seposi: 2025 - 05 - 30 11:39:49
